COMP <GO>
RCKT vs GLSI // EV/EBITDA & P/E VALUATION
Rocket Pharmaceuticals Inc. (NASDAQ) VS. Greenwich LifeSciences Inc. (NASDAQ) • 15-METRIC TALLY: RCKT 1
— GLSI 2
■ METRIC PARITY
LAST: $2.54 (-1.55%) • MKT CAP: $278.8M
valuation
—
LAST: $19.00 (+3.77%) • MKT CAP: $278.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCKT VS. GLSI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RCKT | GLSI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -3.55% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | RCKT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 53.0 | -7.80 | GLSI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $278.8M | $278.9M | -$58.5K | GLSI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RCKT REV | GLSI REV | RCKT GROSS % | GLSI GROSS % | RCKT FCF | GLSI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$190.5M | -$9.9M |
| FY 2024 | $0 | $0 | — | — | -$215.6M | -$7.3M |
| FY 2023 | $0 | $0 | — | — | -$194.9M | -$6.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCKT // BETA —
GLSI // BETA —